An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to 1) evaluate the extent of absorption of a single dose of a
pregabalin controlled release tablet with and without coadministration of erythromycin and 2)
evaluate the safety and tolerability of a single dose of a pregabalin controlled release
tablet with and without coadministration of erythromycin.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.